The global pharma HUB and patient access support service market size is expected to reach USD 7.63 billion by 2033, registering a CAGR of 10.0% from 2025 to 2033, according to a new report by Grand View Research, Inc. The growth is attributed to the significant prevalence of rare and orphan-diseased patients requiring access to specific medicines. Furthermore, the market is driven by an emphasis on establishing a patient-centered ecosystem to provide extensive support to patients throughout their treatment and an increasing demand for tailored solutions aimed at improving patient outcomes.
The prevalence of rare diseases has fueled growth in the pharmaceutical hub and patient access support service market. It is driven by specialized treatment demand, incentives for orphan drug development, the need for patient access support due to rarity, global collaborative efforts, and an expanding market for rare disease treatments. These factors have led to increased investment, innovation, and collaboration in the pharmaceutical industry, particularly in areas related to rare disease research, development, and patient support services.
Up to 36 million people in the EU are affected by rare diseases, which encompass over 6,000 distinct conditions. While some rare diseases impact only a few patients, others can affect as many as 245,000 individuals. About 80% of these diseases have genetic roots, with 70% beginning in childhood. Furthermore, in the U.S., over 10,000 rare diseases impact more than 30 million people. Moreover, it's estimated that 6-8% of the population in India is affected by rare or ultra-rare diseases. Hence, the significant prevalence of rare diseases is expected to contribute to the market growth.
Pharmaceutical companies are prioritizing the needs of patients by creating a patient-centric ecosystem that offers services to support them throughout their therapy journey. This is due to various factors such as lack of proper training, medication non-adherence, and fear of adverse effects, or missed appointments, which can affect a patient's treatment. Patients can access relevant patient service resources and start engaging with the organization as soon as they are prescribed a particular therapy.
With advanced analytics and AI technology, patient services teams can now obtain actionable insights to cater to each patient's individual needs as they progress through their treatment journey. This tailored approach ensures that patients receive the right support at the right time, leading to better therapy outcomes. For instance, companies such as Managed Markets Insight & Technology, LLC, IQVIA, & IntegriChain are offering such solutions in order to overcome barriers to patient access.
Furthermore, the life sciences industry is adapting to the digital era by focusing on value-based care and outcome-driven models that prioritize integrated services. This shift has led to the adoption of technological advancements in integrated solutions to enhance patient access and improve healthcare outcomes. One such example is the PatientLink platform, a new enterprise SaaS by TrialCard. Launched in April 2022, PatientLink simplifies patient access and engagement with Patient Support Programs while improving adherence to medication. It is a highly configurable service that offers an omnichannel experience, enabling leaders in life sciences to meet the needs of a demanding healthcare marketplace through multi-system interoperability.
Request a free sample copy or view report summary: Pharma HUB And Patient Access Support Service Market Report
The program enrollment segment dominated the market with the largest share of 31.2% in 2024.
The integrated services segment dominated the market with the largest share in 2024. With the launch of complex pharmaceutical products and the need for effective market access, manufacturers are looking for a comprehensive approach to streamline their services.
North America pharma HUB and patient access support service market dominated with a revenue share of 48.88% in 2024.
Grand View Research has segmented the global pharma HUB and patient access support service market on the basis of service type, service delivery type, and region:
Pharma HUB And Patient Access Support Service Service Type Outlook (Revenue, USD Million, 2021 - 2033)
Program Enrollment
Order processing
Application processing
Ease of enrollment (through phone, face, portal, or app)
Program data
Treatment Navigators
Process flows and standard operating procedures
Program literature and scripts
Care team training
Systems testing and optimization
Reimbursement Services/Affordability Services
Clinical Educator
Coordination of Specialty Pharmacy/Dispensing
Others
Pharma HUB And Patient Access Support Service Service Delivery Type Outlook (Revenue, USD Million, 2021 - 2033)
Integrated Services
Standalone Services
Pharma HUB And Patient Access Support Service Regional Outlook (Revenue, USD Million, 2021 – 2033)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of Pharma HUB And Patient Access Support Service Market
Valeris (Formerly PharmaCord)
Fortrea
AssistRx
CareMetx, LLC
ConnectiveRx.
Lash Group
McKesson Corporation
Engage
NS Pharma, Inc. (a wholly owned subsidiary of Nippon Shinyaku Co., Ltd.)
Cardinal Health
Envoy Health, Inc.
EVERSANA
United BioSource LLC
Mercalis
Sciensus
"The quality of research they have done for us has been excellent..."